Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Formycon

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

Formycon and Bioeq Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara (Ustekinumab)

Contact the Supplier

Lead Product(s): Ustekinumab

Therapeutic Area: Dermatology Product Name: FYB202

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Bioeq IP AG

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 09, 2020

Details:

The aim of the randomized, double-blind, multi-center Phase III study is to demonstrate the comparability of FYB202 and the reference product Stelara(R) in terms of efficacy, safety and immunogenicity in patients with moderate to severe psoriasis vulgaris.